US FDA has shelved its fast-track “Commissioner’s National Priority Voucher” program aimed at cutting review timelines for drugs addressing national priorities, according to sources familiar with the matter. Launched in June 2025 during the prior administration, the initiative sought to move certain therapies into a one-to-two-month review window. The program faced criticism over whether it could enable preferential treatment tied to political considerations, including pricing outcomes. The reported move signals a shift in how FDA may structure time-limited pathways to speed approvals, with potential implications for companies planning development and regulatory strategy. For biotech sponsors, voucher-style acceleration is relevant primarily for fast-moving programs and competition for scarce review capacity. A pause or reversal can affect clinical development timelines and commercialization planning tied to expected approval dates.